- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00093379
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Capecitabine may stop the growth of tumor cells by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Capecitabine and oxaliplatin may make tumor cells more sensitive to radiation therapy. Combining capecitabine and oxaliplatin with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving capecitabine and oxaliplatin together with radiation therapy works in treating patients with stage II or stage III anal cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine time to treatment failure in patients with stage II-IIIB squamous cell carcinoma of the anal canal treated with capecitabine, oxaliplatin, and radiotherapy (i.e. Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT) shortened to XELOX/XRT).
- Determine the toxic effects of this regimen in these patients.
Secondary
- Determine the complete response rate in patients treated with this regimen.
- Determine 2-year local regional control in patients treated with this regimen.
- Determine 2-year colostomy-free survival in patients treated with this regimen.
- Determine 2-year median overall survival in patients treated with this regimen.
- Determine 2-year progression-free survival in patients treated with this regimen.
OUTLINE: Patients receive oral capecitabine* twice daily on days 1-2, 6-10, 20-24, 27-31, and 41-42, and undergo radiotherapy* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. Patients also receive oxaliplatin intravenous (IV) over 2 hours on days 1, 8, 22, and 29. Treatment continues in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients with T3-4 lesions also receive oral capecitabine twice daily and undergo radiotherapy once daily on days 43 and 44.
Patients are followed at 4-6 and 12 weeks and then periodically thereafter.
PROJECTED ACCRUAL: A total of 71 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030-4009
- M. D. Anderson Cancer Center at University of Texas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Previously untreated patients with histologically proven squamous cell carcinoma of the anal canal.
- American Joint Committee on Cancer (AJCC) stage II-IIIB (TX 1-4, NX, MO).
- Age >/= 16 yrs old.
- Eastern Cooperative Oncology Group (ECOG) Performance Scale (PS) 0-1.
- Adequate organ function including: Absolute neutrophil Count (ANC) >/= 1,500/uL, Platelets >/= 100,000/uL, Total bilirubin </= 1.5 * upper limit of normal (ULN), aspartate aminotransferase (AST or SGOT)/alanine aminotransferase (ALT or SGPT) </= 3 * ULN, Creatinine </= 1.5mg/dL or Creatinine Clearance (CrCL) >/= 50 cc/min.
- Patients may have measurable or non-measurable disease. Patients with measurable disease, as defined by the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria, have at least one lesion that can be accurately measured in at least one dimension with longest diameter to be recorded >/= 20 mm using conventional techniques or >/= 10 mm with spiral CT scan (with minimum lesion size no less than double the slice thickness). Lesions seen on colonoscopy or barium studies are not considered measurable lesions.
- A negative pregnancy test in all women of child-bearing potential, within two weeks of initiating treatment.
- The effects of oxaliplatin and capecitabine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because cytotoxic agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign the written informed consent/authorization document.
Exclusion Criteria:
- Prior chemotherapy with oxaliplatin, capecitabine, or 5-fluorouracil.
- Prior radiation to the pelvis.
- Prior surgery for anal cancer excluding prior biopsy.
- Known history of dihydropyrimidine (DPD) deficiency.
- Known history of hypersensitivity to platinum-containing compounds.
- Peripheral neuropathy of >/= grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) 3.0.
- Calculated creatinine clearance (CrCl) < 50 cc/min.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit adherence with study requirements.
- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation.
- Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with oxaliplatin or capecitabine, breast feeding should be discontinued.
- Because of the known interaction of capecitabine and coumadin, patients taking coumadin will be ineligible. Patients will be requested to discontinue coumadin and utilize Lovenox if agreeable. Patients must have discontinued coumadin for 7 days before initiating therapy.
- No prior malignancies (excluding non-melanomatous skin neoplasms) over the past 5 years.
- HIV-positive patients receiving combination anti-retroviral therapy are excluded from this study because of possible pharmacokinetic interactions with capecitabine or oxaliplatin. This exclusion is for patient safety since patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, and because very few HIV-positive anal canal cancer patients are seen at this institution. This hinders us from accruing enough patients to adequately test the safety of this regimen in this population.
- Patients with symptomatic pulmonary fibrosis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Capecitabine + Oxaliplatin + XRT
Capecitabine (825 mg/m^2 twice a day, Monday-Friday during weeks 1, 2, 4, and 5) and Oxaliplatin (50 mg/m^2, Days 1, 8, 22, 29) during the duration of radiation therapy only.
Radiotherapy once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42.
Participants with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
The final dose of radiation therapy determined by the T stage of the primary tumor.
Radiotherapy = XRT.
|
825 mg/m^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
Other Names:
50 mg/m^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
Other Names:
Undergo radiotherapy* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42.
*Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2 Year Failure Free Survival
Time Frame: 2 years
|
Treatment failure defined as: Biopsy proven residual disease identified 12 -14 weeks after the conclusion of chemoradiation therapy, Treatment-related mortality or Disease recurrence.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Complete Response at 2 Years
Time Frame: 2 Years
|
Response determined by computed tomography (CT)/magnetic resonance imaging (MRI), digital rectal examination, and proctoscopy, and a biopsy performed for clinical suspicion of residual or progressive disease.
Response Evaluation Criteria in Solid Tumors (RECIST) where evaluation of target lesions Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD; Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
|
2 Years
|
Number of Participants With 2-year Colostomy-Free Survival
Time Frame: 2 Years with median study follow up of 19 months
|
Colostomy-free survival reported as number of participants who did not develop local recurrence or require salvage resection with colostomy.
|
2 Years with median study follow up of 19 months
|
2-year Local Regional Control
Time Frame: 2 Years
|
2 Years
|
|
2-Year Median Overall Survival
Time Frame: 2 Years
|
2 Years
|
|
Number of Participants With Progression-Free Survival at 2-Year
Time Frame: 2 Years
|
2 Years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Cathy Eng, MD, M.D. Anderson Cancer Center
- Study Chair: Christopher H. Crane, MD, M.D. Anderson Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Anus Diseases
- Anus Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Capecitabine
- Oxaliplatin
Other Study ID Numbers
- 2003-0874
- P30CA016672 (U.S. NIH Grant/Contract)
- MDA-2003-0874 (Other Identifier: UT MD Anderson Cancer Center)
- SANOFI-MDA-2003-0874
- CDR0000380771 (Registry Identifier: NCI PDQ)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnal Squamous Cell Carcinoma | Stage III Anal Cancer AJCC v8 | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8 | Stage 0 Anal Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Anal Cancer AJCC v8 | Anal Canal Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8United States
-
Sun Yat-sen UniversityEnrolling by invitationAnal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage I | Anal Canal Cancer Stage II | Anal Canal Cancer Stage IIIChina
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingAnal Squamous Cell Carcinoma | Anal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Metastatic Anal Canal Carcinoma | Recurrent Anal Canal Carcinoma | Stage IIIB Anal Canal Cancer | Stage IV Anal Canal CancerUnited States
-
National Cancer Institute (NCI)RecruitingHIV Infection | Anal Squamous Cell Carcinoma | Anal Canal Cloacogenic Carcinoma | Stage III Anal Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Anal Margin Squamous Cell Carcinoma | AIDS-Related Anal Carcinoma | Rectal Squamous Cell Carcinoma | Stage I Anal Cancer AJCC... and other conditionsUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingAnal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Anal Canal Squamous Cell Carcinoma | Anal Margin Squamous Cell Carcinoma | Stage I Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8United States
-
National Cancer Institute (NCI)RecruitingAnal Canal Cloacogenic Carcinoma | Metastatic Anal Squamous Cell Carcinoma | Recurrent Anal Squamous Cell Carcinoma | Stage III Anal Cancer AJCC v8 | Stage IV Anal Cancer AJCC v8 | Unresectable Anal Squamous Cell Carcinoma | Anal Basaloid Squamous Cell CarcinomaUnited States
-
Cardiff UniversityRecruitingAnal Cancer Stage III A | Anal Cancer Stage III BUnited Kingdom, Norway
-
Goethe UniversityActive, not recruitingAnal Cancer | Anal Carcinoma | Anal Cancer Stage III | Anal Cancer Stage IIGermany, Switzerland, Austria
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingAnal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage IIIChina
Clinical Trials on Capecitabine
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Hoffmann-La RocheCompletedBreast Cancer, Colorectal CancerNew Zealand, Australia, United Kingdom
-
Binghe XuHoffmann-La RocheUnknownSkin Diseases | Neoplasms by Site | Breast Neoplasms | Breast Diseases | Neoplasm MetastasisChina
-
Jules Bordet InstituteCompletedBreast Cancer | Elderly PatientsBelgium
-
Samsung Medical CenterCompletedAdvanced or Recurrent Esophageal Squamous Cell CarcinomaKorea, Republic of
-
Fudan UniversityCompletedMetastatic Breast CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Hoffmann-La RocheUnknownCarcinoma, Invasive Ductal, BreastChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruiting
-
Jiangxi Provincial Cancer HospitalNot yet recruitingNasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer